145 related articles for article (PubMed ID: 36723821)
1. Multimerin 1 aids in the progression of ovarian cancer possibly via modulation of DNA damage response and repair pathways.
Saini A; Kumar V; Tomar AK; Sharma A; Yadav S
Mol Cell Biochem; 2023 Oct; 478(10):2395-2403. PubMed ID: 36723821
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Multimerin 1 (MMRN1) expression in ovarian cancer.
Saini A; Chandra KB; Kumar V; Mathur SR; Sharma JB; Kumar S; Yadav S
Mol Biol Rep; 2020 Dec; 47(12):9459-9468. PubMed ID: 33263168
[TBL] [Abstract][Full Text] [Related]
3. Platelet adhesion to multimerin 1 in vitro: influences of platelet membrane receptors, von Willebrand factor and shear.
Tasneem S; Adam F; Minullina I; Pawlikowska M; Hui SK; Zheng S; Miller JL; Hayward CP
J Thromb Haemost; 2009 Apr; 7(4):685-92. PubMed ID: 19175495
[TBL] [Abstract][Full Text] [Related]
4. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
Meng E; Mitra A; Tripathi K; Finan MA; Scalici J; McClellan S; Madeira da Silva L; Reed E; Shevde LA; Palle K; Rocconi RP
PLoS One; 2014; 9(9):e107142. PubMed ID: 25216266
[TBL] [Abstract][Full Text] [Related]
5. APE1 overexpression promotes the progression of ovarian cancer and serves as a potential therapeutic target.
Wen X; Lu R; Xie S; Zheng H; Wang H; Wang Y; Sun J; Gao X; Guo L
Cancer Biomark; 2016 Sep; 17(3):313-322. PubMed ID: 27802207
[TBL] [Abstract][Full Text] [Related]
6. The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding.
Parker DN; Tasneem S; Farndale RW; Bihan D; Sadler JE; Sebastian S; de Groot PG; Hayward CP
Thromb Haemost; 2016 Jul; 116(1):87-95. PubMed ID: 27052467
[TBL] [Abstract][Full Text] [Related]
7. Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1.
Xiao M; Guo J; Xie L; Yang C; Gong L; Wang Z; Cai J
Mol Cancer Res; 2020 Mar; 18(3):436-447. PubMed ID: 31722968
[TBL] [Abstract][Full Text] [Related]
8. Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer.
Jin Y; Xu X; Wang X; Kuang H; Osterman M; Feng S; Han D; Wu Y; Li M; Guo H
Oncotarget; 2016 Aug; 7(31):49710-49721. PubMed ID: 27391345
[TBL] [Abstract][Full Text] [Related]
9. Multimerin-1 and cancer: a review.
Posner MG
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35132992
[TBL] [Abstract][Full Text] [Related]
10. Analyses of cellular multimerin 1 receptors: in vitro evidence of binding mediated by alphaIIbbeta3 and alphavbeta3.
Adam F; Zheng S; Joshi N; Kelton DS; Sandhu A; Suehiro Y; Jeimy SB; Santos AV; Massé JM; Kelton JG; Cramer EM; Hayward CP
Thromb Haemost; 2005 Nov; 94(5):1004-11. PubMed ID: 16363244
[TBL] [Abstract][Full Text] [Related]
11. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
12. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
13. MTA1 promotes cell proliferation via DNA damage repair in epithelial ovarian cancer.
Yang QY; Li JH; Wang QY; Wu Y; Qin JL; Cheng JJ; Qiu J
Genet Mol Res; 2014 Dec; 13(4):10269-78. PubMed ID: 25501238
[TBL] [Abstract][Full Text] [Related]
14. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
Clin Cancer Res; 2015 Jul; 21(14):3187-95. PubMed ID: 25825478
[TBL] [Abstract][Full Text] [Related]
15. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
Kim MK; James J; Annunziata CM
BMC Cancer; 2015 Mar; 15():196. PubMed ID: 25884494
[TBL] [Abstract][Full Text] [Related]
16. Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation.
Jeimy SB; Fuller N; Tasneem S; Segers K; Stafford AR; Weitz JI; Camire RM; Nicolaes GA; Hayward CP
Thromb Haemost; 2008 Dec; 100(6):1058-67. PubMed ID: 19132231
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and immunological role of MMRN1: a rising star in cancer.
Zhou Q; Liu Y; Zhou J; Zhang W
Nucleosides Nucleotides Nucleic Acids; 2024 May; ():1-22. PubMed ID: 38715238
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
19. UV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites occur independently of p53-replication protein A interaction in p53 wild type and mutant ovarian carcinoma cells.
Riva F; Zuco V; Vink AA; Supino R; Prosperi E
Carcinogenesis; 2001 Dec; 22(12):1971-8. PubMed ID: 11751427
[TBL] [Abstract][Full Text] [Related]
20. ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.
Kim JY; Bahar E; Lee JY; Chang S; Kim SH; Park EY; Do SI; Yoon H; Kim HS
Cell Death Dis; 2022 Mar; 13(3):239. PubMed ID: 35293383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
